<DOC>
	<DOC>NCT02973776</DOC>
	<brief_summary>Vasoconstriction study with LEO 90100</brief_summary>
	<brief_title>Vasoconstriction Trial With LEO 90100 Aerosol Foam</brief_title>
	<detailed_description>This study compares the pharmacodynamic activity of LEO 90100 with Dermovate cream, Diprosone ointment, Elocon cream, Locoid ointment and LEO 90100 vehicle using a human skin blanching test</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Hydrocortisone-17-butyrate</mesh_term>
	<criteria>Subjects demonstrating adequate vasoconstriction to Diprosone® ointment within 15 days prior to dosing (unoccluded application of Diprosone® ointment for 46 hours must show a visual score of skin blanching of at least one unit (visual scale (04)). Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn). Abnormal pigmentation of the skin or skin type that could, in any way, confound interpretation of the trial results (skin type V and VI on the Fitzpatrick scale). Female subjects who are breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>